Bristol-Myers Squibb announces outcomes of BMS-708163 Stage II study on Alzheimer’s Bristol-Myers Squibb Organization today announced the results of a Stage II study evaluating the security and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-average Alzheimer’s disease. The randomized, double-blind, placebo-controlled study demonstrated that BMS-708163 doses below 100 mg/time provide a potential therapeutic windowpane for additional evaluation in Stage III registrational research.The drug functions by increasing your body’s sensitivity to insulin, an integral protein necessary for digestion that diabetics don’t adequately produce. People with diabetes cannot properly breakdown carbohydrates, either because their bodies usually do not produce plenty of insulin or due to resistance to insulin. They’re at higher risk for center attacks, kidney complications, blindness and other significant complications. Avandia was Glaxo’s third best-selling drug in 2006 with U.S.